| Revista: | Revista do Instituto de Medicina Tropical de Sao Paulo |
| Base de datos: | |
| Número de sistema: | 000547840 |
| ISSN: | 0036-4665 |
| Autors: | Alves, Késsia Caroline Souza1 Guimarães, Jander Matos3 Almeida, Maria Edilene Martins de4 Mariúba, Luís André Morais1 |
| Institucions: | 1Instituto Leônidas e Maria Deane, Fundação Oswaldo Cruz, Manaus, Amazonas. Brasil 2Universidade Federal do Amazonas, Instituto de Ciências Biológicas, Manaus, Amazonas. Brasil 3Universidade do Estado do Amazonas, Centro Multiusuário para Análises de Fenômenos Biomédicos, Manaus, Amazonas. Brasil 4Fundação Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro. Brasil 5Universidade Federal do Amazonas, Manaus, Amazonas. Brasil |
| Any: | 2022 |
| Volum: | 64 |
| País: | Brasil |
| Idioma: | Inglés |
| Resumen en inglés | Despite the many efforts of researchers around the world, there is currently no effective vaccine for malaria. Numerous studies have been developed to find vaccine antigens that are immunogenic and safe. Among antigen candidates, Plasmodium falciparum merozoite surface protein 3 (MSP3) has stood out in a number of these studies for its ability to induce a consistent and protective immune response, also being safe for use in humans. This review presents the main studies that explored MSP3 as a vaccine candidate over the last few decades. MSP3 formulations were tested in animals and humans and the most advanced candidate formulations are MSP3-LSP, a combination of MSP3 and LSP1, and GMZ2 (a vaccine based on the recombinant protein fusion GLURP and MSP3) which is currently being tested in phase II clinical studies. This brief review highlights the history and the main formulations of MSP3-based vaccines approaches against P. falciparum . |
| Keyword: | Malaria, MSP3, Plasmodium falciparum, Vaccine, Immunity |
| Text complet: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
